Provided by Tiger Trade Technology Pte. Ltd.

BioNTech SE

95.70
-0.0350-0.04%
Volume:609.72K
Turnover:58.60M
Market Cap:24.04B
PE:-12.31
High:97.46
Open:94.46
Low:93.92
Close:95.73
52wk High:124.00
52wk Low:79.52
Shares:251.20M
Float Shares:109.00M
Volume Ratio:0.68
T/O Rate:0.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.7726
EPS(LYR):-5.5184
ROE:-9.30%
ROA:-5.41%
PB:1.21
PE(LYR):-17.34

Loading ...

BioNTech Price Target Cut to $114.00/Share from $115.00 by Morgan Stanley

Dow Jones
·
Yesterday

Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Labcorp Holdings (LH) and Surgery Partners (SGRY)

TIPRANKS
·
Yesterday

Why Vaxcyte Chose A 1.5% Convertible

Macro World​
·
Yesterday

BioNTech CEO Uğur Şahin Disposes of 93,000 Shares Worth $9,031,514.30

Reuters
·
Yesterday

From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run

Bellwether Stocks Movement
·
Oct 06

BioNTech SE (BNTX) Gets a Buy from Morgan Stanley

TIPRANKS
·
Oct 05

One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet

Bellwether Stocks Movement
·
Oct 05

Merck Doubled Off Its Lows — And Analysts Still See More Room

Bellwether Stocks Movement
·
Oct 05

CSL Bets $1.6 Billion on a Drug That Hasn't Finished Phase 2

Bellwether Stocks Movement
·
Oct 05

Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs

Macro World​
·
Oct 03

23.3% Vs 14.8%: Lilly's New Data Just Changed The Obesity Drug Playbook

Bellwether Stocks Movement
·
Oct 03

BioNTech CEO Uğur Şahin Disposes of $3,304,076 in Common Shares

Reuters
·
Oct 03

Warburg Research Keeps Their Buy Rating on Deutsche Boerse (0H3T)

TIPRANKS
·
Oct 02

Berenberg Bank Sticks to Its Buy Rating for Bechtle Aktiengesellschaft (0DPM)

TIPRANKS
·
Oct 02

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02

Novartis Bets $7.8 Billion On MRNA Beyond Vaccines

Options & Short Sell
·
Oct 02

BioNTech CEO Uğur Şahin Disposes of $6.48 Million in Common Shares

Reuters
·
Oct 01

BioNTech Steps Deeper Into Lung Cancer With New Dareon-Rosetta35 Trial

TIPRANKS
·
Oct 01

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

GlobeNewswire
·
Sep 29